Multiple Sclerosis, Chronic Progressive clinical trials

The registry lists 244 studies for Multiple Sclerosis, Chronic Progressive across more than 10 countries. 53 are recruiting or about to start. 160 of them are mainly about Multiple Sclerosis, Chronic Progressive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Multiple Sclerosis, Chronic Progressive studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 121
Recruiting: 37
Active, not recruiting: 21
Terminated: 19
Status unknown: 19
Not yet recruiting: 13

Phase

Phase 2: 75
Phase 1: 56
Phase 3: 39
Phase 4: 5
Early Phase 1: 4

Where

United States: 105
United Kingdom: 35
Germany: 32
France: 32
Canada: 31
Spain: 29

Who runs them

Novartis Pharmaceuticals (13) · Hoffmann-La Roche (9) · Rigshospitalet, Denmark (6) · Shirley Ryan AbilityLab (5) · Johns Hopkins University (5) · Biogen (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Bayer (4)

What is being tested here

Drugs under test in Multiple Sclerosis, Chronic Progressive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Ocrelizumab	2	8	10
Remibrutinib	2	1	2
Orelabrutinib	2	2	2
Rituximab	1	3	8
Cladribine	1	2	2
Mivocabtagene autoleucel	1	0	2
Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112	1	0	1
Indapamide	1	0	1
Autologous mRNA-transfected Anti-BCMA-CAR T-lymphocytes SYS6020	1	0	1
Dasatinib	1	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open · Antimetabolites 1 open · Corticosteroids 4

Coming up

13phase 3 studies under way

18studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jun 2027Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). · Phase 3 · Institute of Psychiatry and Neurology, Warsaw
Nov 2026Functional Outcomes From Diets in Multiple Sclerosis · University of Alabama at Birmingham
Nov 2026Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases · Polina Stepensky
Nov 2026Home Based Functional Balance Intervention for Multiple Sclerosis · University of Illinois at Chicago
Jan 2027Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) · National Institute of Allergy and Infectious Diseases (NIAID)
Jan 2027Senolytics for Secondary Progressive MS · Ohio State University
Feb 2027Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis · Emmanuelle Waubant, MD PhD
Feb 2027Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration · University Hospital, Antwerp
Apr 2027KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis · Kyverna Therapeutics
Apr 2027Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients · University of Michigan

Who these studies take

Of the 37 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (19%) set no upper age limit and 24 (65%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (16%) take healthy volunteers.

Recruiting studies that take each age, of 37
Age	Women	Men
10	0 (0%)	0 (0%)
18	34 (92%)	34 (92%)
30	36 (97%)	36 (97%)
40	37 (100%)	37 (100%)
50	37 (100%)	37 (100%)
65	28 (76%)	28 (76%)
75	18 (49%)	18 (49%)
85	9 (24%)	9 (24%)

Across all 244 studies, recruiting or not: 73% stop at 75 or younger and 56% at 65; 2% take children; <1% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Multiple Sclerosis, Chronic Progressive studies take

Of 25 phase 2 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 41 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	44 mo17–56 · 20 studies	—	—
Phase 2	41 mo23–55 · 25 studies	—	—
Phase 3	61 mo52–83 · 20 studies	—	—
Interventional, no phase	33 mo18–44 · 36 studies	—	33 mo18–44 · 35 studies
Observational	37 mo34–87 · 18 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 12, 2026.

Newly registered1

REAL-MS: Observational Database Study of AHSCT and MS TherapiesOct 27, 2026NCT07899502

Studies

Recruiting first, then most recently updated. Showing 50 of 244. Browse all 244 → or search them.